Steve Kregel, PhD
@stevekregel.bsky.social
Cancer Biologist studying prostate cancer at Loyola University Chicago. Kregellab.com
Reposted by Steve Kregel, PhD
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer https://www.biorxiv.org/content/10.1101/2025.07.18.664790v1
July 20, 2025 at 3:48 AM
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer https://www.biorxiv.org/content/10.1101/2025.07.18.664790v1
Reposted by Steve Kregel, PhD
Before WW2, UK led the world in many scientific domains, but its focus on centralized government laboratories rather than university partnerships stifled post-war commercialization. By contrast, USA channeled wartime research funds into universities www.nature.com/articles/d41...
How the United States became a science superpower — and how quickly it could crumble
US global dominance in science was no accident, but a product of a far-seeing partnership between public and private sectors to boost innovation and economic growth.
www.nature.com
April 17, 2025 at 8:09 PM
Before WW2, UK led the world in many scientific domains, but its focus on centralized government laboratories rather than university partnerships stifled post-war commercialization. By contrast, USA channeled wartime research funds into universities www.nature.com/articles/d41...
Reposted by Steve Kregel, PhD
This is just horrible.
The FY25 CR obliterates the already small funding allocations for the development of new treatments for patients with pancreatic cancer, lung cancer and glioblastoma.... for what purpose?
These are three of the deadliest types of cancer.
The FY25 CR obliterates the already small funding allocations for the development of new treatments for patients with pancreatic cancer, lung cancer and glioblastoma.... for what purpose?
These are three of the deadliest types of cancer.
They are cutting cancer research. They are cutting cancer research. They can deny it all they want, but they are cutting cancer research. These are the cuts being made the DoD CDMRP cancer funding mechanism www.fightcancer.org/sites/defaul...
March 27, 2025 at 11:26 AM
This is just horrible.
The FY25 CR obliterates the already small funding allocations for the development of new treatments for patients with pancreatic cancer, lung cancer and glioblastoma.... for what purpose?
These are three of the deadliest types of cancer.
The FY25 CR obliterates the already small funding allocations for the development of new treatments for patients with pancreatic cancer, lung cancer and glioblastoma.... for what purpose?
These are three of the deadliest types of cancer.
Proud to announce the publication of my master’s student Audris’s work on the pro-survival role of the linage specific, AR-cofactor NKX3.1 in prostate cancer cells! Take a look 👀 www.mdpi.com/2072-6694/17...
The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells
Background/Objectives: Prostate cancer (PCa) is the second leading cause of cancer-related death in men. The increase in incidence rates of more advanced and aggressive forms of the disease year-to-ye...
www.mdpi.com
January 18, 2025 at 2:06 PM
Proud to announce the publication of my master’s student Audris’s work on the pro-survival role of the linage specific, AR-cofactor NKX3.1 in prostate cancer cells! Take a look 👀 www.mdpi.com/2072-6694/17...
Reposted by Steve Kregel, PhD
Download our database of 492 (!) funding opportunities for EARLY-CAREER FACULTY AND RESEARCHERS.
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
November 17, 2024 at 4:38 PM
Download our database of 492 (!) funding opportunities for EARLY-CAREER FACULTY AND RESEARCHERS.
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).
Download freely here: research.jhu.edu/rdt/funding-...
